Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 12, 2022

FDA approves Genentech’s sNDA for influenza therapy in children

The US Food and Drug Administration (FDA) has approved Genentech’s supplemental new drug application (sNDA) for xofluza (baloxavir marboxil) to treat influenza in children.

FDA approves Genentech’s sNDA for influenza therapy in children